GlassScriptPhysician profile
Sanjay Sahay
NPI 1790897734
$9,217.69
in general payments reported to CMS, 2019-2025
48 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $1,087 · 2021: $1,253 · 2022: $1,390 · 2023: $1,479 · 2024: $993 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,027 · Education: $40.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.27 |
| Education | $40.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,100.45 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Amgen INC. | $653.11 | 2019-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $598.77 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $555.90 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $546.17 | 2019-2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $495.07 | 2021-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $458.69 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $450.19 | 2021-2025 | Korlym |
| Lilly USA, LLC | $432.99 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $388.10 | 2019-2024 | |
| Insulet Corporation | $387.58 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $320.48 | 2019-2022 | |
| Dexcom, INC. | $274.51 | 2020-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $266.53 | 2019-2022 | |
| Pfizer INC. | $229.34 | 2019-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Sahay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.